ACH ACCENDRA HEALTH INC/VA/
Wholesale-Medical, Dental & Hospital Equipment & Supplies · OTC · SEC CIK 75252 · Fiscal year ends 12/31
Financial factors as of 2026-03-31 (2026Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY-0.0%
TTM net income YoY-195.8%
TTM EPS YoY-195.6%
Revenue 3-yr CAGR-35.4%
Net income 3-yr CAGR—
Margins
Gross margin46.0%
Operating margin0.9%
Net margin-39.8%
FCF margin-10.7%
EBITDA margin8.2%
Returns
ROE-2,037.6%
ROA-29.8%
ROIC (approx.)1.0%
Asset turnover0.75x
Leverage & solvency
Liabilities / assets119.2%
Debt / equity—
Current ratio0.49x
Interest coverage0.22x
Cash quality & payout
Operating cash flow / net income0.11x
Accruals ratio-26.5%
Payout ratio—
Capex / revenue6.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $2.76B | $2.68B |
| Cost of revenue | $1.47B | $1.40B |
| Gross profit | $1.29B | $2.22B |
| R&D expense | — | $13.00M |
| SG&A expense | $1.07B | $1.08B |
| Operating income | $27.46M | -$217.73M |
| Interest expense | $107.18M | $107.57M |
| Pretax income | -$101.95M | -$329.88M |
| Income tax | $729,000 | $20.85M |
| Net income | -$1.10B | -$362.69M |
| EBITDA | $241.98M | -$36.45M |
| EPS (basic) | -14.31 | -4.73 |
| EPS (diluted) | -14.31 | -4.73 |
| Weighted avg. shares (diluted) | 76.90M | 76.74M |
| Balance sheet | ||
| Cash & equivalents | $281.99M | $27.57M |
| Inventory | $74.44M | $67.58M |
| Current assets | $547.87M | $2.02B |
| PP&E, net | $256.16M | $249.28M |
| Goodwill | $1.23B | $1.23B |
| Intangibles | $136.47M | $210.06M |
| Total assets | $2.45B | $4.66B |
| Current liabilities | $947.08M | $1.85B |
| Short-term debt | $250.00M | $42.87M |
| Long-term debt | $1.80B | $1.80B |
| Total debt | $2.05B | $1.84B |
| Total liabilities | $2.91B | $4.07B |
| Shareholders' equity | -$460.98M | $586.36M |
| Net debt | $1.77B | $1.81B |
| Shares outstanding | 76.39M | 77.20M |
| Cash flow statement | ||
| Operating cash flow | -$101.79M | $161.50M |
| Capital expenditure | $190.96M | $170.29M |
| Free cash flow | -$292.75M | -$8.79M |
| Investing cash flow | $144.42M | -$116.53M |
| Financing cash flow | $188.08M | -$267.60M |
| Depreciation & amortization | $214.52M | $181.28M |
| Stock-based compensation | $12.87M | $16.64M |
| Share buybacks | $10.18M | — |
Free plan shows the latest 2 periods; Pro shows all 18 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.